Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

NCT01329913 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: MK-6325
DRUG: Placebo to MK-6325
DRUG: MK-6325
DRUG: Placebo to MK-6325
DRUG: MK-6325
DRUG: Placebo to MK-6325

Sponsor

Merck Sharp & Dohme LLC